Zita C.
- Country
- Czechia
- Department
- Ustav klinicke imunologie a alergologie
Research Overview
- Phase II Randomized Double‑Blind Dose‑Ranging Study of Inhaled Glycopyrronium Bromide Add‑On to Budesonide/Formoterol in Children 4–<12 years with Asthma
- Efficacy and Safety Evaluation of PQ Grass 27600 SU in Pediatric Patients with Grass Pollen-Induced Seasonal Allergic Rhinitis/Rhinoconjunctivitis
- Efficacy and Safety Evaluation of Verekitug (UPB-101) in Adults with Severe Asthma: A Phase 2 Randomized, Double-blind, Placebo-controlled Study
Data & Insights
Has run more than one trial at 30 of 184 partner sites.
Specializations
Respiratory Medicine
The investigator specializes in the treatment and management of severe asthma and its various manifestations, with particular focus on developing innovative therapeutic approaches for patients with persistent symptoms.
- Rescue medication optimization
- Clinical asthma exacerbations
- Advanced inhaler technologies
Studies include evaluation of combination therapies utilizing fluticasone propionate and albuterol sulfate delivery systems.
Allergic Conditions
Conducts research in seasonal allergic rhinitis and rhinoconjunctivitis, with special emphasis on pediatric populations affected by grass pollen allergies.
- Pediatric allergy management
- Long-term immunotherapy outcomes
- Grass pollen induced allergies
Focuses on evaluating sustained therapeutic responses in children with seasonal allergic conditions.
Novel Therapeutics
Investigates emerging treatments for respiratory conditions, including the evaluation of verekitug for severe asthma management.
- Biological therapy assessment
- Exacerbation reduction strategies
- Treatment efficacy evaluation
Explores comparative effectiveness of new therapeutic agents against established treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.